Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Nature of Operations and Business Activities (Detail Textuals)

Nature of Operations and Business Activities (Detail Textuals) - USD ($)	1 Months Ended		2 Months Ended	6 Months Ended
	Jul. 31, 2020	Apr. 29, 2020	Aug. 31, 2020	Jun. 30, 2020	Aug. 04, 2020	Apr. 22, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Nov. 01, 2018
Nature Of Operations And Business Activities [Line Items]
Accumulated deficit				$ (35,935,178)				$ (32,173,282)
Stockholders' deficit				(3,094,424)			$ (1,702,897)	548,058	$ (11,641,442)	$ (27,864,191)	$ (15,562,252)
Working capital deficit				(1,929,168)
Cash and cash equivalents				$ 102,524				$ 1,829,977
Description of senior management's compensation plan				During March 2020, the Company approved a plan to defer up to 50% of the members of senior management’s compensation and 100% of the Board of Director and committee fees indefinitely.
Paycheck Protection Program Promissory Note (PPP Note)
Nature Of Operations And Business Activities [Line Items]
Principal amount of promissory Note						$ 116,700
Subsequent Event
Nature Of Operations And Business Activities [Line Items]
Warrants to purchase shares of common stock issued and outstanding					8,166,667
Description of senior management's compensation plan			In August 2020, subsequent to closing the August 2020 Financing, the Board of Directors determined that the Company has been sufficiently financed and authorized the Company to pay the deferred compensation and fee balances together with a retention bonus of 10% of such balance.
Exercise Price					$ 0.075
Multi-Draw Credit Agreement
Nature Of Operations And Business Activities [Line Items]
Principal amount of promissory Note									$ 4,000,000
Exercise Price									$ 0.50			$ 0.50
Amended and Restated Multi-Draw Credit Agreement
Nature Of Operations And Business Activities [Line Items]
Principal amount of credit facility		$ 20,000,000
Credit facility advances		6,000,000
Draw downs loans In aggregate principal amount		$ 6,000,000
Warrants to purchase shares of common stock issued and outstanding		7,500,000
Interest rates per annum		7.00%
Maturity date		Oct. 05, 2022
Exercise Price		$ 0.50
fourth amended and Restated Multi-Draw Credit Agreement
Nature Of Operations And Business Activities [Line Items]
Credit facility advances per month				$ 150,000
Fifth Amended And Restated Multi Draw Credit Agreement [Member]
Nature Of Operations And Business Activities [Line Items]
Credit facility advances per month				$ 300,000
Securities Purchase Agreement with H.C. Wainwright & Co., LLC \| Subsequent Event
Nature Of Operations And Business Activities [Line Items]
Number Of Common Stock Units Sold	56,333,334
Number Of Pre Funded Units Sold	60,333,334
Gross Proceeds Of Units Sold	$ 6,939,667
Term Of Warrants	5 years
Securities Purchase Agreement with H.C. Wainwright & Co., LLC \| Subsequent Event \| Common Stock Warrants
Nature Of Operations And Business Activities [Line Items]
Exercise Price	$ 0.06
Securities Purchase Agreement with H.C. Wainwright & Co., LLC \| Subsequent Event \| Pre-funded Warrants
Nature Of Operations And Business Activities [Line Items]
Exercise Price	$ 0.001